TOPICS / PLAYER

Genentech / Roche

Genentech (Roche) — BioNTech's partner on autogene cevumeran and a broader personalized-cancer-vaccine collaboration.

Topic2 items2026-09-02 – 2026-09-04

Players

Moderna62 Merck45 Transgene9 BioNTech4 Evaxion4 Geneos Therapeutics3 Genentech / Roche2 NEC / NEC OncoImmunity1 Nouscom1 Nykode Therapeutics1

Clinical

BioNTech cancer vaccine trial halted after survival imbalance - European Biotechnology Magazine

Log in here to read the desired article. BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients under observation. The setback comes…

news · brief 2026-09-04 · published 2026-08-31

Clinical

Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.

europepmc · brief 2026-09-02 · published 2026-09-01